TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Prevalence of majordermatitis types by key countries, 2018 4.2. Recent industrydevelopments such as mergers & acquisitions 4.3. Pipeline analysis 4.4. Patent landscape 4.5. Reimbursement scenario bykey countries 4.6. Regulatory scenario for keycountries 5. Global Dermatitis DrugsMarket Analysis, Insights and Forecast, 2014-2025 5.1. Key Findings / Summary 5.2. Market Analysis, Insightsand Forecast – By Drug Class 5.2.1. Calcineurin Inhibitors 5.2.2. PDE4 Inhibitors 5.2.3. Corticosteroids 5.2.4. Biologics 5.2.5. Others 5.3. Market Analysis, Insightsand Forecast – By Disease Indication 5.3.1. Atopic Dermatitis 5.3.2. Contact Dermatitis 5.3.3. Others 5.4. Market Analysis, Insightsand Forecast – By Distribution Channel 5.4.1. Hospital Pharmacy 5.4.2. Retail Pharmacy 5.4.3. Online Pharmacy 5.5. Market Analysis, Insightsand Forecast – By Country 5.5.1. North America 5.5.2. Europe 5.5.3. Asia pacific 5.5.4. Rest of World 6. North America DermatitisDrugs Market Analysis, Insights and Forecast, 2014-2025 6.1. Key Findings / Summary 6.2. Market Analysis – By DrugClass 6.2.1. Calcineurin Inhibitors 6.2.2. PDE4 Inhibitors 6.2.3. Corticosteroids 6.2.4. Biologics 6.2.5. Others 6.3. Market Analysis – ByDisease Indication 6.3.1. Atopic Dermatitis 6.3.2. Contact Dermatitis 6.3.3. Others 6.4. Market Analysis – ByDistribution Channel 6.4.1. Hospital Pharmacy 6.4.2. Retail Pharmacy 6.4.3. Online Pharmacy 6.5. Market Analysis – ByCountry 6.5.1. U.S. 6.5.2. Canada 7. Europe Dermatitis DrugsMarket Analysis, Insights and Forecast, 2014-2025 7.1. Key Findings / Summary 7.2. Market Analysis – By Drug Class 7.2.1. Calcineurin Inhibitors 7.2.2. PDE4 Inhibitors 7.2.3. Corticosteroids 7.2.4. Biologics 7.2.5. Others 7.3. Market Analysis – ByDisease Indication 7.3.1. Atopic Dermatitis 7.3.2. Contact Dermatitis 7.3.3. Others 7.4. Market Analysis – ByDistribution Channel 7.4.1. Hospital Pharmacy 7.4.2. Retail Pharmacy 7.4.3. Online Pharmacy 7.5. Market Analysis – ByCountry 7.5.1. U.K. 7.5.2. Germany 7.5.3. France 7.5.4. Spain 7.5.5. Italy 7.5.6. Scandinavia 7.5.7. Rest of Europe 8. Asia pacific DermatitisDrugs Market Analysis, Insights and Forecast, 2014-2025 8.1. Key Findings / Summary 8.2. Market Analysis – By DrugClass 8.2.1. Calcineurin Inhibitors 8.2.2. PDE4 Inhibitors 8.2.3. Corticosteroids 8.2.4. Biologics 8.2.5. Others 8.3. Market Analysis – ByDisease Indication 8.3.1. Atopic Dermatitis 8.3.2. Contact Dermatitis 8.3.3. Others 8.4. Market Analysis – ByDistribution Channel 8.4.1. Hospital Pharmacy 8.4.2. Retail Pharmacy 8.4.3. Online Pharmacy 8.5. Market Analysis – ByCountry 8.5.1. Japan 8.5.2. China 8.5.3. India 8.5.4. Australia 8.5.5. Southeast Asia 8.5.6. Rest of Asia Pacific 9. Rest of World DermatitisDrugs Market Analysis, Insights and Forecast, 2014-2025 9.1. Key Findings / Summary 9.2. Market Analysis – By DrugClass 9.2.1. Calcineurin Inhibitors 9.2.2. PDE4 Inhibitors 9.2.3. Corticosteroids 9.2.4. Biologics 9.2.5. Others 9.3. Market Analysis – ByDisease Indication 9.3.1. Atopic Dermatitis 9.3.2. Contact Dermatitis 9.3.3. Others 9.4. Market Analysis – ByDistribution Channel 9.4.1. Hospital Pharmacy 9.4.2. Retail Pharmacy 9.4.3. Online Pharmacy 9.5. Market Analysis – ByCountry 10. Competitive Analysis 10.1. Key Industry Developments 10.2. Global Market ShareAnalysis (2017) 10.3. Competition Dashboard 10.4. Comparative Analysis –Major Players 10.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability)) 10.5.1. Valeant Pharmaceuticals 10.5.2. Astellas Pharma US, Inc. 10.5.3. Pfizer, Inc. 10.5.4. Mylan 10.5.5. Bayer AG 10.5.6. Allergan 10.5.7. LEO Pharma 10.5.8. Regeneron Pharmaceuticals,Inc. 10.5.9. Anacor Pharmaceuticals,Inc. 11. Strategic Recommendations

Valeant Pharmaceuticals Astellas Pharma US, Inc. Pfizer, Inc. Mylan Bayer AG Allergan LEO Pharma Regeneron Pharmaceuticals, Inc. Anacor Pharmaceuticals, Inc.